Shanghai Fosun Pharmaceutical (Group) Co Ltd (SFOSF)
1.532
0.00 (0.00%)
USD |
OTCM |
Apr 16, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 4.094B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -47.85% |
Valuation | |
PE Ratio | 12.17 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.7068 |
Price to Book Value | 0.6353 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.0590 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.7237 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 83.02% |
Profile
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices and medical diagnosis, Pharmaceutical distribution and retail, and Other business operations. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
URL | https://www.fosunpharma.com |
Investor Relations URL | https://www.fosunpharma.com/en/investor/investor-index.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Blend |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jul. 31, 2023 |
Ratings
Profile
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices and medical diagnosis, Pharmaceutical distribution and retail, and Other business operations. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
URL | https://www.fosunpharma.com |
Investor Relations URL | https://www.fosunpharma.com/en/investor/investor-index.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Blend |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jul. 31, 2023 |